FDA Approves Atacicept for IgA Nephropathy - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

  • By

  • Kathryn Wighton

  • July 7, 2026

  • 3 min

Share

Clinical Scorecard: FDA Approves Atacicept for IgA Nephropathy

At a Glance

CategoryDetail
ConditionPrimary Immunoglobulin A Nephropathy
Key MechanismsTargets B-cell activating factor and A Proliferation Inducing Ligand, proteins involved in immune cell survival and maturation.
Target PopulationAdults with primary IgA nephropathy at risk for disease progression.
Care SettingClinical trial and outpatient management.

Key Highlights

  • Atacicept is the first approved therapy for primary IgA nephropathy.
  • Demonstrated a 46% reduction in proteinuria at 9 months compared to placebo.
  • Accelerated approval granted based on proteinuria reduction.
  • Patients must be evaluated for infections before treatment.
  • Ongoing clinical trial required to verify long-term kidney function benefits.

Guideline-Based Recommendations

Diagnosis

  • Biopsy-confirmed primary IgA nephropathy.

Management

  • Monitor for proteinuria and assess kidney function.

Monitoring & Follow-up

  • Evaluate for active infections before treatment initiation and during therapy.

Risks

  • Increased risk of infections and injection site reactions.

Patient & Prescribing Data

Adults with biopsy-confirmed primary IgA nephropathy.

Atacicept administered subcutaneously at 150 mg once weekly.

Clinical Best Practices

  • Do not administer live vaccines within 30 days prior to treatment or during treatment.
  • Monitor patients for signs of infection during therapy.

Related Resources & Content

Original Source(s)

FDA Approves Atacicept for IgA Nephropathy

  • by Kathryn Wighton

  • July 7, 2026

Related Content

Side Effects: Bro Science, Actually

Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.

PTSD May Be Linked to Accelerated Aging

Integrated proteomic and metabolomic analyses identified redox-metabolic signatures associated with chronic posttraumatic stress disorder and accelerated biological aging across multiple organ systems.

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.